← 返回

源自 NK 细胞的外泌体:改变侵袭性乳腺癌的免疫治疗

英文原题:Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.

查看英文原题

Exosomes derived from natural killer cells: transforming immunotherapy for aggressive breast cancer.

PubMed 2025/03/18(内容时间) Med Oncol Q2 · IF 4.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

NK 细胞来源的外泌体(NK-Exos)因其固有的潜在抗肿瘤效应,作为免疫调节剂和免疫治疗药物在抗癌领域具有巨大前景。它们利用这些纳米级囊泡将细胞毒性分子,如穿孔素、颗粒酶和miRNAs,直接递送至癌细胞以将其杀死,从而避免免疫抑制。NK-Exos通过调节TME以激活免疫应答并抑制免疫抑制因子,对治疗侵袭性乳腺癌具有特殊疗效。生物工程学的进展拓展了NK-Exos的治疗潜力,使其能够精确靶向肿瘤细胞并高效递送治疗性载荷,包括小RNAs和化疗药物。在工程化NK-Exos中,已证明其可高效增强癌细胞对凋亡的敏感性、减少肿瘤生长并克服耐药性。联合应用时,NK-Exos与放疗、化疗或检查点抑制剂产生协同作用,增强治疗效果并最大限度降低全身毒性。本综述强调了NK-Exos在乳腺癌治疗中的关键作用、其与联合治疗的整合,以及需要进一步研究以克服现有局限并充分实现其临床潜力。

展开英文摘要原文

Natural killer cell-derived exosomes (NK-Exos) hold great promise as immune modulators and immunotherapeutics against cancer due to their intrinsically latent anti-tumor effects. They use these nanosized vesicles to deliver cytotoxic molecules, such as perforin, granzymes, and miRNAs, directly to cancer cells to kill them, avoiding immune suppression. NK-Exos has particular efficacy for treating aggressive breast cancer by modulating the TME to activate the immune response and suppress immunosuppressive factors. Bioengineering advances have extended the therapeutic potential of NK-Exos, which permits precise tumor cell targeting and efficient delivery of therapeutic payloads, including small RNAs and chemotherapeutic agents.

In engineered NK-Exos, sensitization of cancer cells to apoptosis, reduction of tumor growth, and resistance to drugs have been demonstrated to be highly effective. When combined, NK-Exos synergizes with radiotherapy, chemotherapy, or checkpoint inhibitors, enhancing therapeutic efficacy, and minimizing systemic toxicity.

This review emphasizes the critical role of NK-Exos in breast cancer treatment, their integration into combination therapies, and the need for further research to overcome existing limitations and fully realize their clinical potential.

论文信息

作者
Alfawaz Altamimi AS、Arockia Babu M、Afzal M、Bishoyi AK、Roopashree R、Saini S、Sharma RSK、Pathak PK
第一作者单位
Department of Pharmaceutical Chemistry, College of Pharmacy, Prince Sattam Bin Abdulaziz University, 11942, Al Kharj, Saudi Arabia.United States
通讯作者单位
Research and Enterprise, University of Cyberjaya, Persiaran Bestari, Cyber 11, 63000, Cyberjaya, Selangor, Malaysia. ashok.cyberjaya@outlook.com.Malaysia
文献类型
综述
期刊
Medical oncology (Northwood, London, England)2025 Mar 18
原文标识
PubMed 40100465 · DOI 10.1007/s12032-025-02647-y